Treatment of plasma cell dyscrasias with lenalidomide (Q37176044)

18 August 2017

1 reference

title

Treatment of plasma cell dyscrasias with lenalidomide (English)

1 reference

18 August 2017

E Kastritis

2

0 references

Athanasios Dimopoulos

series ordinal

1

object named as

M A Dimopoulos

1 reference

18 August 2017

3

S V Rajkumar

1 reference

18 August 2017

29 May 2008

1 reference

18 August 2017

1 reference

18 August 2017

22

1 reference

18 August 2017

7

1 reference

18 August 2017

1343-1353

1 reference

https://scigraph.springernature.com/pub.10.1038/leu.2008.123

18 August 2017

0 references

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.123

Antitumor activity of thalidomide in refractory multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.123

Overview of cancer epigenetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.123

Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.123

Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.123

Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.123

Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.123

Advances in biology of multiple myeloma: clinical applications

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.123

Immunomodulatory drugs inhibit expression of cyclooxygenase-2 from TNF-alpha, IL-1beta, and LPS-stimulated human PBMC in a partially IL-10-dependent manner

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.123

Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.123

Lenalidomide inhibits proliferation of Namalwa CSN.70 cells and interferes with Gab1 phosphorylation and adaptor protein complex assembly

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.123

Multiple myeloma: a prototypic disease model for the characterization and therapeutic targeting of interactions between tumor cells and their local microenvironment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.123

Thalidomide induces apoptosis in human monocytes by using a cytochrome c-dependent pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.123

Thalidomide costimulates primary human T lymphocytes, preferentially inducing proliferation, cytokine production, and cytotoxic responses in the CD8+ subset

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.123

Thalidomide and a thalidomide analogue drug costimulate virus-specific CD8+ T cells in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.123

Thalidomide stimulates T cell responses and interleukin 12 production in HIV-infected patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.123

Immunomodulatory drug costimulates T cells via the B7-CD28 pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.123

Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.123

The evolution of thalidomide and its IMiD derivatives as anticancer agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.123

Immunomodulatory drug lenalidomide (CC-5013, IMiD3) augments anti-CD40 SGN-40-induced cytotoxicity in human multiple myeloma: clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.123

Novel thalidomide analogues display anti-angiogenic activity independently of immunomodulatory effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.123

Thalidomide downregulates angiogenic genes in bone marrow endothelial cells of patients with active multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.123

Endothelial cells and VEGF in vascular development

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.123

A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.123

Thalidomide and CC-5013 in multiple myeloma: the University of Arkansas experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.123

Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.123

BiRD (Biaxin [clarithromycin]/Revlimid [lenalidomide]/dexamethasone) combination therapy results in high complete- and overall-response rates in treatment-naive symptomatic multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.123

Thrombotic complications in patients with newly diagnosed multiple myeloma treated with lenalidomide and dexamethasone: benefit of aspirin prophylaxis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.123

High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.123

Thalidomide alone or with dexamethasone for previously untreated multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.123

Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.123

Superiority of thalidomide and dexamethasone over vincristine-doxorubicindexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.123

Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.123

Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.123

Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.123

A new standard of care for elderly patients with myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.123

Melphalan, prednisone, and lenalidomide treatment for newly diagnosed myeloma: a report from the GIMEMA--Italian Multiple Myeloma Network

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.123

Transplantation for amyloidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.123

Poor tolerance to high doses of thalidomide in patients with primary systemic amyloidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.123

The combination of thalidomide and intermediate-dose dexamethasone is an effective but toxic treatment for patients with primary amyloidosis (AL).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.123

The activity of lenalidomide with or without dexamethasone in patients with primary systemic amyloidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.123

Lenalidomide and dexamethasone in the treatment of AL amyloidosis: results of a phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.123

Update on treatment recommendations from the Third International Workshop on Waldenstrom's macroglobulinemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.123

Pharmacokinetics of lenalidomide in subjects with various degrees of renal impairment and in subjects on hemodialysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.123

Hypersensitivity pneumonitis-like syndrome associated with the use of lenalidomide.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.123

Impact of lenalidomide therapy on stem cell mobilization and engraftment post-peripheral blood stem cell transplantation in patients with newly diagnosed myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.123

Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.123

Low-molecular-weight heparins for the treatment of acute coronary syndrome and venous thromboembolism in patients with chronic renal insufficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.123

Dermatologic adverse effects of lenalidomide therapy for amyloidosis and multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.123

S.T.E.P.S.: a comprehensive program for controlling and monitoring access to thalidomide

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.123

Lenalidomide and thalidomide: mechanisms of action--similarities and differences

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.123

7 January 2021

Immunomodulation by thalidomide and thalidomide analogues

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.123

7 January 2021

Thalidomide: a novel template for anticancer drugs

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.123

7 January 2021

Lenalidomide (Revlimid), in combination with cyclophosphamide and dexamethasone (RCD), is an effective and tolerated regimen for myeloma patients

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.123

7 January 2021

Lenalidomide and pegylated liposomal doxorubicin-based chemotherapy for relapsed or refractory multiple myeloma: safety and efficacy

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.123

7 January 2021

Long-term results of response to therapy, time to progression, and survival with lenalidomide plus dexamethasone in newly diagnosed myeloma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.123

7 January 2021

A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.123

7 January 2021

Advances in the treatment of amyloidosis

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.123

7 January 2021

Tolerability and efficacy of thalidomide for the treatment of patients with light chain-associated (AL) amyloidosis

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.123

7 January 2021

Review of 1027 patients with newly diagnosed multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.123

7 January 2021

Identifiers

DOI

10.1038/LEU.2008.123

1 reference

PubMed ID

18509355

Dimensions Publication ID

18 August 2017

0 references

1 reference

PubMed ID

18509355